安科恒益品牌怎么样 申请店铺
安徽安科恒益药业有限公司隶属于安徽安科生物工程(集团)股份有限公司(股票代码:300009)。安徽安科恒益药业有限公司是专业从事药品研究、生产、销售的制药企业。公司注册资本3800万元，占地80亩，建筑面积28000m,建有七条GMP标准化生产线，分别为:固体制剂生产线两条、糖浆生产线、肿瘤药制剂生产线、头孢专线、青霉素专线、原料药生产线。公司拥有57个文号，41个品种，是安微省内生产规模大，剂型较全的化药生产企业之一。
随着企业规模不断的壮大，公司将发展新品种、加强品种建设，引进新品种，重视品种的更新改良的工作列入了公司发展规划，相继引进了富马酸替诺福韦二吡味酯片、甲苯磺酸索拉非尼片、多烯磷脂酰胆碱胶囊、头孢地尼片等新药，成立了“安徽省小分子药物工程技术研究中心”，并组建了“博士后科研工作站”。
安徽安科恒益药业有限公司作为国内具有影响力的生物制药企业安科生物的全资子公司,将不断依托自身以及集团公司雄厚的科技研发力量和资金支持，在新药开发、质量标准研究、药物新剂型和制药关键技术与工艺等领域，形成了持续创新和持续发展的能力，提升核心竞争力。公司始终如一的贯彻执行GMP规范要求，保障产品质量，为人类的健康事业做出贡献。
Anhui Anke Hengyi Pharmaceutical Co., Ltd. is subordinate to Anhui Anke Bioengineering (Group) Co., Ltd. (Stock Code: 300009). Anhui Anke Hengyi Pharmaceutical Co., Ltd. is a pharmaceutical enterprise specializing in drug research, production and sales. The registered capital of the company is 38 million yuan, covering an area of 80 mu and a building area of 28000m. There are seven GMP standardized production lines, including two solid preparation production lines, syrup production lines, tumor drug preparation production lines, cephalosporin production lines, penicillin production lines and API production lines. The company has 57 document numbers and 41 varieties. It is one of the chemical drug manufacturers with large production scale and complete dosage forms in Anwei province. With the continuous expansion of the enterprise scale, the company has included the development of new varieties, strengthening the construction of varieties, introducing new varieties, and paying attention to the renewal and improvement of varieties in the company's development plan. It has successively introduced new drugs such as tenofovir dipivoxil fumarate tablets, sorafenib toluenesulfonate tablets, polyene phosphatidylcholine capsules, cefdini tablets, and established "Anhui small molecule pharmaceutical industry" Cheng technology research center "and set up a" postdoctoral research workstation ". Anhui Anke Hengyi Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Anke biology, a domestic influential biopharmaceutical enterprise, We will continue to rely on our own and the group's strong scientific and technological research and development strength and financial support to form the ability of continuous innovation and development in the fields of new drug development, quality standard research, new drug dosage forms and key pharmaceutical technologies and processes, and enhance the core competitiveness. The company consistently implements GMP requirements, ensures product quality and contributes to human health.
本文链接： https://brand.waitui.com/9ca29876e.html 联系电话：05622655853
浙公网安备 33011802001999号
